Hope Valley AI - Integrated risk-informed AI-based weak signals screening solutions

Building the fourth-generation AI platform for rare events risk prediction and early weak signals screening

We are the fourth-generation AI designers building the first GEN-IV AI platform to capture and characterize rare events with multi-year risk prediction and early weak signals detection, years before they occur.

HOPE®, the first smart modular breast health digital clinic on Smartphone, serves as a super-demonstrator of our integrated GEN-IV AI Platform.

Learn more about HOPE® (🇫🇷)

HOPE®, the first module of our smart modular breast health digital clinic, is a mobile application we launched in October 8, 2025, as a Class I CE-marked digital medical device, with registration number (01)03770040298008(8012)V1.0.6. HOPE® is available on App Store and Google Play, free of charge during the 12-month pilot period, until Pink October 2026. It is not a diagnostic tool and does not replace medical advice or a clinical examination by a healthcare professional. Please consult your doctor in case of doubt or unusual observation.

Before a rare event speaks, weak signals whisper

40%

of rare events in cancer or complex systems often emerge from preventable conditions linked to avoidable systemic risk factors.

40%

of rare events develop in complex systems or individuals whose increased risk potential could have been identified years earlier.

HOPE VALLEY AI transforms complex, imbalanced, multimodal and multi-physics data into predictive weak signals, enabling integrated multi-year risk prediction through trustworthy fourth-generation AI solutions capable of early detection and characterization of rare events, years before they occur.

The GEN-IV AI platform is a cross-domain technology designed to operate across multiple fields.

We started with breast cancer as our first rare event use case, as we are committed to fighting breast cancer through risk-informed prevention and early detection of its weak signals, years before it occurs.

We are following Marie Curie’s legacy from a century ago by bringing nuclear technology and innovation to the fight against cancer.

Sources: INCA, Santé Publique France, American Cancer Society, WHO, Nature Women’s Health, JRC Science for Policy Report (European Commission 2021).

Proud to be backed by

…and committed business angels, partners and sponsors.

2025 Hope Valley AI. All rights reserved.

Terms of Service